MedTrace Logo

Identifying Biomarkers for Chronic Pain After Breast Cancer Treatment.

NCT05507034 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-12-27

No results posted yet for this study

Summary

Up to 40% of women experience chronic pain after treatment for breast cancer, and this pain is often very disabling. However, chronic pain after breast cancer remains under-recognised and undertreated. An effective and patient-tailored approach of (chronic) pain after breast cancer indeed requires a thorough knowledge and

evaluation of the pain. In daily clinical practice, however, guidelines for a comprehensive diagnosis of pain in cancer patients and survivors are lacking. Further research in this topic is crucial for an efficient, preventive as well as curative, approach of pain after breast cancer. Besides the high prevalence and the important impact of pain in this population, the breast cancer population is also an ideal population to study chronic pain and its natural time course in different stages, since most patients start pain-free, but almost half of them end up

with chronic pain. Therefore, this study aims to map biomarkers (both predictive, prognostic and diagnostic) for chronic pain after breast cancer treatment. We will study possible biopsychosocial biomarkers in

relation to (chronic) pain and monitor their temporal changes from the moment of diagnosis until 1 year after surgery. The potential biomarkers are situated within the medical imaging of the brain, measurements of pain sensitivity and psychological variables.

Conditions

Interventions

DIAGNOSTIC_TEST

Biomarkers

Each intervention is performed at 4 timepoints namely: before surgery, i.e. baseline (T0), 1-3 weeks post-surgery (T1), 3 months post-surgery (T2) and 1 year post-surgery (T4)

Sponsors & Collaborators

  • University Hospital, Antwerp

    collaborator OTHER

  • Fund for Scientific Research, Flanders, Belgium

    collaborator OTHER

  • Universiteit Antwerpen

    lead OTHER

Principal Investigators

  • Mira Meeus, Prof. · Universiteit Antwerpen

  • An De Groef, Prof. · Universiteit Antwerpen

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-04
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05507034 on ClinicalTrials.gov